12:00 AM
Sep 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

NX-1207: Phase III ongoing

Nymox said a safety monitoring committee found no significant safety concerns in the double-blind, placebo-controlled, U.S. Phase III NX02-0018 trial of a single intraprostatic injection of 2.5 mg NX-1207. Nymox said it...

Read the full 138 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >